Aunins John G. 4
4 · Seres Therapeutics, Inc. · Filed Jan 28, 2020
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Exercise/Conversion
COMMON STOCK
2020-01-26+12,500→ 105,250 total - Exercise/Conversion
RESTRICTED STOCK UNITS
2020-01-26−12,500→ 0 total→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The restricted stock units are fully vested and do not have an expiration date.